Similarly, small molecule allosteric inhibitors of MKP-1 would be highly attractive target for therapeutic intervention in metabolic diseases including, insulin resistance, T2D and obesity. This evidence concerns the gene DUSP1 and obesity due to melanocortin 4 receptor deficiency.